Document is current
Any future updates will be listed below
-
Authors
Minoyan, Nanor
Høj, Stine Bordier
Jutras-Aswad, Didier
Larney, Sarah
Martel-Laferrière, Valérie
Sylvestre, Marie-Pierre
Bruneau, Julie https://orcid.org/0000-0002-0470-0720
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (MOP135260)
Canadian Institutes of Health Research (MOP210232)
Canadian Institutes of Health Research (SMN139149)
Fonds de Recherche du Québec - Santé (FRSQ5227)
- License Information
-
More Information
Article History
Accepted: 17 November 2023
First Online: 4 December 2023
Declarations
:
: Ethics approval for the HEPCO study was obtained through the institutional review board of the Centre de recherche du Centre hospitalier de l’Université de Montréal (subject to annual renewal). The study is conducted in full conformity with the Declaration of Helsinki, Canadian, and international standards of Good Clinical Practice (Health Canada and International Conference on Harmonization Guidelines) and applicable provincial government and institutional regulations. Participants receive a small monetary compensation for their time and provide written informed consent at enrolment.
: NM, SBH and MPS have no conflicts of interest to declare. DJA received study materials from Cardiol Therapeutics for a publicly funded clinical trial not related to this manuscript’s theme. SL has received advisory board fees from Gilead Sciences, unrelated to the current work. VML receives funding from Gilead and Merck and has received advisory board fees from AbbVie. JB receives funding from Gilead Sciences and has received advisory board fees from Gilead Sciences, AbbVie and Cepheid Sciences, outside the scope of this work.
